

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-85 (Cancelled).

86. (Previously Presented) A method for the treatment of osteomyelitis comprising:
administering a composition comprising a ligand-complexed radionuclide to a subject
suffering from osteomyelitis under conditions such that said osteomyelitis is reduced.

87. (Previously Presented) The method of claim 1 wherein the ligand is a bone-targeting
ligand.

88. (Previously Presented) The method of claim 87 wherein said ligand is a macrocyclic
aminophosphonic acid.

89. (Previously Presented) The method of claim 88, wherein said ligand is 1,4,7,10-
tetraazacyclododecanetetramethylenephosphonic acid (DOTMP).

90. (Previously Presented) The method of claim 87, wherein said ligand is selected from the
group consisting of ethylenediaminetetramethylenephosphonic acid,
diethylenetriaminepentamethylenephosphonic acid,
hydroxyethylethylenediaminetrimethylenephosphonic acid, nitrilotrimethylenephosphonic acid,
tris(2-aminoethyl)aminehexamethylenephosphonic acid, methylene diphosphonate,
hydroxymethylenediphosphonate, hydroxyethylidene diphosphonate, and ethane-1-hydroxy-1,1-
diphosphonic acid.

91. (Previously Presented) The method of claim 90, wherein said ligand is
ethylenediaminetetramethylenephosphonic acid.

92. (Previously Presented)The method of claim 86, wherein said radionuclide is selected from the group consisting of Arsenic-77, Molybdenum-99, Rhodium-105, Lutetium-177, Cadmium-115, Antimony-122, Promethium-149, Osmium-193, Gold-198, Thorium-200, Samarium-153, Yttrium-90, Gadolinium-159, Rhenium-186, Rhenium-188, and Holmium-166.

93. (Previously Presented)The method of claim 89 wherein the ligand-complexed radionuclide is ^{166}Ho -DOTMP.

94. (Previously Presented)The method of claim 86 wherein the ligand-complexed radionuclide is administered by injection.

95. (Previously Presented)The method of claim 86 wherein the ligand is administered by infusion.